Yanming Wei
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Yanming Wei has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
Bo Han
College of Basic Medicine, Shanxi University of Chinese Medicine, Jinzhong, China
5 shared publicationsKun Zhou
Shanxi Institute of Energy, Taiyuan, China
5 shared publicationsHuifang Li
College of Chinese Medicine and Food Engineering, Shanxi University of Chinese Medicine, Jinzhong, China
4 shared publicationsYinxia Chang
College of Chinese Medicine and Food Engineering, Shanxi University of Chinese Medicine, Jinzhong, China
4 shared publicationsPengcheng Li
College of Chinese Medicine and Food Engineering, Shanxi University of Chinese Medicine, Jinzhong, China
3 shared publicationsYuerui Su
College of Chinese Medicine and Food Engineering, Shanxi University of Chinese Medicine, Jinzhong, China
3 shared publications
Latest Publications
- 10 July 2026
- Published by Elsevier in Food and Chemical Toxicology
- Vol. 216, 116270
Triptolide-induced hepatotoxicity is mediated by NLRP3-dependent pyroptosis and inhibited by mitophagy
- 10 July 2026
- Published by Elsevier in Food and Chemical Toxicology
- Vol. 216, 116270
Triptolide-induced hepatotoxicity is mediated by NLRP3-dependent pyroptosis and inhibited by mitophagy
- Open Access
- 26 March 2026
- Published by Spandidos Publications in International Journal of Molecular Medicine
- Vol. 57 (6) , 1-28
Crosstalk between autophagy and ferroptosis in liver diseases (Review)
Ferroptosis is a novel form of regulated cell death triggered by iron‑dependent accumulation in lipid peroxidation. Multiple intracellular catabolic processes and signaling pathways are implicated in ferroptosis regulation. One is autophagy, which delivers cytoplasmic materials to lysosomes for degradation and is critical for the preservation of cellular homeostasis. The discovered role of autophagy in driving ferroptosis have motivated further explorations of the functional interactions and signal pathways between ferroptosis and autophagy, particularly their crosstalk in the pathogenesis or treatment for various liver diseases, such as drug‑induced liver injury, toxin‑induced liver injury, liver fibrosis and hepatocellular carcinoma. The present review presented an in‑depth overview of research on the crosstalk between autophagy and ferroptosis in diverse liver diseases, including the ones aforementioned. The diverse regulatory mechanisms involved in this process are also analyzed to open a new perspective on the interpretation of liver diseases manifestations and provide potential targets for drug discovery and effective intervene.
- 26 March 2026
- Published by Spandidos Publications in International Journal of Molecular Medicine
- Vol. 57 (6) , 1-28
Open AccessCrosstalk between autophagy and ferroptosis in liver diseases (Review)
Ferroptosis is a novel form of regulated cell death triggered by iron‑dependent accumulation in lipid peroxidation. Multiple intracellular catabolic processes and signaling pathways are implicated in ferroptosis regulation. One is autophagy, which delivers cytoplasmic materials to lysosomes for degradation and is critical for the preservation of cellular homeostasis. The discovered role of autophagy in driving ferroptosis have motivated further explorations of the functional interactions and signal pathways between ferroptosis and autophagy, particularly their crosstalk in the pathogenesis or treatment for various liver diseases, such as drug‑induced liver injury, toxin‑induced liver injury, liver fibrosis and hepatocellular carcinoma. The present review presented an in‑depth overview of research on the crosstalk between autophagy and ferroptosis in diverse liver diseases, including the ones aforementioned. The diverse regulatory mechanisms involved in this process are also analyzed to open a new perspective on the interpretation of liver diseases manifestations and provide potential targets for drug discovery and effective intervene.
- 20 May 2025
- Published by Elsevier in Food and Chemical Toxicology
- Vol. 203, 115568
Activation of Rab7-mediated lipophagy is required for triptolide to induce ferroptosis in hepatic cells
- 20 May 2025
- Published by Elsevier in Food and Chemical Toxicology
- Vol. 203, 115568
Activation of Rab7-mediated lipophagy is required for triptolide to induce ferroptosis in hepatic cells
- Open Access
- 20 April 2023
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 25 (6) , 1-15
Autophagy in the pharmacological activities of celastrol (Review)
Celastrol, a natural compound extracted from the traditional Chinese medicinal herb Tripterygium wilfordii Hook F, possesses broad‑spectrum pharmacological properties. Autophagy is an evolutionarily conserved catabolic process through which cytoplasmic cargo is delivered to the lysosomes for degradation. Autophagy dysregulation contributes to multiple pathological processes. Therefore, targeting autophagic activity is a promising therapy for various diseases, as well as a drug‑development strategy. According to previous studies, autophagy is specifically targeted and may be altered in response to celastrol treatment, highlighting that autophagy modulation is an important mechanism underlying the therapeutic efficacy of celastrol for the treatment of various diseases. The present study summarizes the currently available information regarding the role of autophagy in the effect of celastrol to exert anti‑tumor, anti‑inflammatory, immunomodulatory, neuroprotective, anti‑atherosclerosis, anti‑pulmonary fibrosis and anti‑macular degeneration activities. The diverse signaling pathways involved are also analyzed to provide insight into the mechanisms of action of celastrol and thereby pave the way for establishing celastrol as an efficacious autophagy modulator in clinical practice.
- 20 April 2023
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 25 (6) , 1-15
Open AccessAutophagy in the pharmacological activities of celastrol (Review)
Celastrol, a natural compound extracted from the traditional Chinese medicinal herb Tripterygium wilfordii Hook F, possesses broad‑spectrum pharmacological properties. Autophagy is an evolutionarily conserved catabolic process through which cytoplasmic cargo is delivered to the lysosomes for degradation. Autophagy dysregulation contributes to multiple pathological processes. Therefore, targeting autophagic activity is a promising therapy for various diseases, as well as a drug‑development strategy. According to previous studies, autophagy is specifically targeted and may be altered in response to celastrol treatment, highlighting that autophagy modulation is an important mechanism underlying the therapeutic efficacy of celastrol for the treatment of various diseases. The present study summarizes the currently available information regarding the role of autophagy in the effect of celastrol to exert anti‑tumor, anti‑inflammatory, immunomodulatory, neuroprotective, anti‑atherosclerosis, anti‑pulmonary fibrosis and anti‑macular degeneration activities. The diverse signaling pathways involved are also analyzed to provide insight into the mechanisms of action of celastrol and thereby pave the way for establishing celastrol as an efficacious autophagy modulator in clinical practice.
- Open Access
- 17 March 2021
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 21 (5) , 1-14
MicroRNAs as crucial mediators in the pharmacological activities of triptolide (Review)
Triptolide is the main bioactive constituent isolated from the Chinese herb Tripterygium wilfordii Hook F., which possesses a variety of pharmacological properties. MicroRNAs (miRNAs/miRs) are short non‑coding RNAs that regulate gene expression post‑transcriptionally. miRNAs are implicated in several intracellular processes, whereby their dysregulation contributes to pathogenesis of various diseases. Thus, miRNAs have great potential as biomarkers and therapeutic targets for diseases, and are implicated in drug treatment. Previous studies have reported that specific miRNAs are targeted, and their expression levels can be altered following exposure to triptolide. Thus, miRNAs are emerging as crucial mediators in the pharmacological activities of triptolide. The present review summarizes current literature on miRNAs as target molecules in the pharmacological activities of triptolide, including antitumor, anti‑inflammatory, immunosuppressive, renal protective, cardioprotective, antiangiogenesis activities and multiorgan toxicity effects. In addition, the diverse signaling pathways involved are discussed to provide a comprehensive understanding of the underlying molecular mechanisms of triptolide in the regulation of target miRNAs.
- 17 March 2021
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 21 (5) , 1-14
Open AccessMicroRNAs as crucial mediators in the pharmacological activities of triptolide (Review)
Triptolide is the main bioactive constituent isolated from the Chinese herb Tripterygium wilfordii Hook F., which possesses a variety of pharmacological properties. MicroRNAs (miRNAs/miRs) are short non‑coding RNAs that regulate gene expression post‑transcriptionally. miRNAs are implicated in several intracellular processes, whereby their dysregulation contributes to pathogenesis of various diseases. Thus, miRNAs have great potential as biomarkers and therapeutic targets for diseases, and are implicated in drug treatment. Previous studies have reported that specific miRNAs are targeted, and their expression levels can be altered following exposure to triptolide. Thus, miRNAs are emerging as crucial mediators in the pharmacological activities of triptolide. The present review summarizes current literature on miRNAs as target molecules in the pharmacological activities of triptolide, including antitumor, anti‑inflammatory, immunosuppressive, renal protective, cardioprotective, antiangiogenesis activities and multiorgan toxicity effects. In addition, the diverse signaling pathways involved are discussed to provide a comprehensive understanding of the underlying molecular mechanisms of triptolide in the regulation of target miRNAs.
- 25 July 2019
- Published by SAGE Publications in International Journal of Toxicology
- Vol. 38 (5) , 436-444
Autophagy in Triptolide-Mediated Cytotoxicity in Hepatic Cells
Triptolide is a major active ingredient isolated from the traditional Chinese herb Tripterygium wilfordii Hook F. However, its use in clinical practice is limited due to its severe hepatotoxicity. Autophagy, a highly conserved intracellular process, is essential for maintaining cytoplasmic homeostasis. Considering that abnormalities in autophagy are closely associated with drug-mediated hepatotoxicity, we applied human normal liver HL7702 cells to elucidate the roles of autophagy in triptolide-induced hepatotoxicity. Our study revealed that triptolide was cytotoxic to HL7702 cells. It markedly increased autophagosome formation and expression of autophagy-related proteins, namely Beclin1 and microtubule-associated protein 1 light chain 3II, and induced oxidative stress. These proautophagic effects were counteracted by pretreatment with N-acetylcysteine, a reactive oxygen species scavenger. Moreover, the pharmacological suppression of autophagy further exacerbated triptolide-elicited decrease in cell viability, increase in lactate dehydrogenase leakage, and activation of apoptosis proteases (caspase 3 and caspase 9). Our findings suggest that triptolide-induced oxidative stress consequently enhances autophagic activity, and autophagy is a cytoprotective mechanism against triptolide-induced cytotoxicity in HL7702 cells.
- 25 July 2019
- Published by SAGE Publications in International Journal of Toxicology
- Vol. 38 (5) , 436-444
Autophagy in Triptolide-Mediated Cytotoxicity in Hepatic Cells
Triptolide is a major active ingredient isolated from the traditional Chinese herb Tripterygium wilfordii Hook F. However, its use in clinical practice is limited due to its severe hepatotoxicity. Autophagy, a highly conserved intracellular process, is essential for maintaining cytoplasmic homeostasis. Considering that abnormalities in autophagy are closely associated with drug-mediated hepatotoxicity, we applied human normal liver HL7702 cells to elucidate the roles of autophagy in triptolide-induced hepatotoxicity. Our study revealed that triptolide was cytotoxic to HL7702 cells. It markedly increased autophagosome formation and expression of autophagy-related proteins, namely Beclin1 and microtubule-associated protein 1 light chain 3II, and induced oxidative stress. These proautophagic effects were counteracted by pretreatment with N-acetylcysteine, a reactive oxygen species scavenger. Moreover, the pharmacological suppression of autophagy further exacerbated triptolide-elicited decrease in cell viability, increase in lactate dehydrogenase leakage, and activation of apoptosis proteases (caspase 3 and caspase 9). Our findings suggest that triptolide-induced oxidative stress consequently enhances autophagic activity, and autophagy is a cytoprotective mechanism against triptolide-induced cytotoxicity in HL7702 cells.
- 1 January 2019
- Published by Elsevier in Neuroscience Letters
- Vol. 690, 106-111
Beclin1 decreases the RIPA-insoluble fraction of amyotrophic lateral sclerosis-linked SOD1 mutant via autophagy
- 1 January 2019
- Published by Elsevier in Neuroscience Letters
- Vol. 690, 106-111
Beclin1 decreases the RIPA-insoluble fraction of amyotrophic lateral sclerosis-linked SOD1 mutant via autophagy
- 4 September 2018
- Published by Springer Nature in Chinese Journal of Integrative Medicine
- Vol. 25 (3) , 233-240
Triptolide, A Potential Autophagy Modulator
As a major active component extracted from traditional Chinese herb Tripterygium wilfordii Hook F, triptolide exhibits multiple pharmacological effects. Autophagy is an evolutionary conserved intracellular catabolic process involved in cytoplasmic materials degradation. Autophagic dysfunction contributes to the pathologies of many human diseases, which makes it a promising therapeutic target. Recent studies have shown that triptolide exerts neuroprotection, anti-tumor activities, organ toxicity, and podocyte protection by modulating autophagy. This article highlights the current information on triptolide-modulated autophagy, analyzes the possible pathways involved, and describes the crosstalk between autophagy and apoptosis modulated by triptolide, in hope of providing implications for the roles of autophagy in pharmacological effects of triptolide and expanding its novel usage as an autophagy modulator.
- 4 September 2018
- Published by Springer Nature in Chinese Journal of Integrative Medicine
- Vol. 25 (3) , 233-240
Triptolide, A Potential Autophagy Modulator
As a major active component extracted from traditional Chinese herb Tripterygium wilfordii Hook F, triptolide exhibits multiple pharmacological effects. Autophagy is an evolutionary conserved intracellular catabolic process involved in cytoplasmic materials degradation. Autophagic dysfunction contributes to the pathologies of many human diseases, which makes it a promising therapeutic target. Recent studies have shown that triptolide exerts neuroprotection, anti-tumor activities, organ toxicity, and podocyte protection by modulating autophagy. This article highlights the current information on triptolide-modulated autophagy, analyzes the possible pathways involved, and describes the crosstalk between autophagy and apoptosis modulated by triptolide, in hope of providing implications for the roles of autophagy in pharmacological effects of triptolide and expanding its novel usage as an autophagy modulator.
- Open Access
- 1 January 2014
- Published by Medknow in Neural Regeneration Research
- Vol. 9 (1) , 16-24
Autophagic induction of amyotrophic lateral sclerosislinked Cu/Zn superoxide dismutase 1 G93A mutant in NSC34 cells
Previous studies have confirmed that the beclin 1 complex plays a key role in the initial stage of autophagy and deregulated autophagy might involve in amyotrophic lateral sclerosis. However, the mechanism underlying altered autophagy associated with the beclin 1 complex remains unclear. In this study, we transfected the Cu/Zn superoxide dismutase 1 G93A mutant protein into the motor neuron-like cell line NSC34 cultured in vitro. Western blotting and co-immunoprecipitation showed that the Cu/Zn superoxide dismutase 1 G93A mutant enhanced the turnover of autophagic marker microtubule-associated protein light chain 3II (LC3II) and stimulated the conversion of EGFP-LC3I to EGFP-LC3II, but had little influence on the binding capacity of the autophagy modulators ATG14L, rubicon, UVRAG, and hVps34 to beclin 1 during autophagosome formation. These results suggest that the amyotrophic lateral sclerosis-linked Cu/Zn superoxide dismutase 1 G93A mutant can upregulate autophagic activity in NSC34 cells, but that this does not markedly affect beclin 1 complex components.
- 1 January 2014
- Published by Medknow in Neural Regeneration Research
- Vol. 9 (1) , 16-24
Open AccessAutophagic induction of amyotrophic lateral sclerosislinked Cu/Zn superoxide dismutase 1 G93A mutant in NSC34 cells
Previous studies have confirmed that the beclin 1 complex plays a key role in the initial stage of autophagy and deregulated autophagy might involve in amyotrophic lateral sclerosis. However, the mechanism underlying altered autophagy associated with the beclin 1 complex remains unclear. In this study, we transfected the Cu/Zn superoxide dismutase 1 G93A mutant protein into the motor neuron-like cell line NSC34 cultured in vitro. Western blotting and co-immunoprecipitation showed that the Cu/Zn superoxide dismutase 1 G93A mutant enhanced the turnover of autophagic marker microtubule-associated protein light chain 3II (LC3II) and stimulated the conversion of EGFP-LC3I to EGFP-LC3II, but had little influence on the binding capacity of the autophagy modulators ATG14L, rubicon, UVRAG, and hVps34 to beclin 1 during autophagosome formation. These results suggest that the amyotrophic lateral sclerosis-linked Cu/Zn superoxide dismutase 1 G93A mutant can upregulate autophagic activity in NSC34 cells, but that this does not markedly affect beclin 1 complex components.
- Open Access
- 30 October 2013
- Published by Asian Pacific Organization for Cancer Prevention in Asian Pacific Journal of Cancer Prevention
- Vol. 14 (10) , 5663-5669
Triptolide Inhibits Histone Methyltransferase EZH2 and Modulates the Expression of Its Target Genes in Prostate Cancer Cells
Triptolide Inhibits Histone Methyltransferase EZH2 and Modulates the Expression of Its Target Genes in Prostate Cancer Cells EZH2;EZH2 target genes;prostate cancer (PCa);Triptolide; The histone methyltransferase EZH2 (enhancer of zeste homolog 2) plays critical roles in prostate cancer (PCa) development and is a potential target for PCa treatment. Triptolide possesses anti-tumor activity, but it is unknown whether its therapeutic effect relates with EZH2 in PCa. Here we described EZH2 as a target for Triptolide in PCa cells. Our data showed that Triptolide suppressed PCa cell growth and reduced the expression of EZH2. Overexpression of EZH2 attenuated the Triptolide induced cell growth inhibition. Moreover, Triptolide treatment of PC-3 cells resulted in elevated mRNA levels of target genes (ADRB2, CDH1, CDKN2A and DAB2IP) negatively regulated by EZH2 as well as reduced mRNA levelsan of EZH2 positively regulated gene (cyclin D1). Our findings suggest the PCa cell growth inhibition mediated by Triptolide might be associated with downregulation of EZH2 expression and the subsequent modulation of target genes.
- 30 October 2013
- Published by Asian Pacific Organization for Cancer Prevention in Asian Pacific Journal of Cancer Prevention
- Vol. 14 (10) , 5663-5669
Open AccessTriptolide Inhibits Histone Methyltransferase EZH2 and Modulates the Expression of Its Target Genes in Prostate Cancer Cells
Triptolide Inhibits Histone Methyltransferase EZH2 and Modulates the Expression of Its Target Genes in Prostate Cancer Cells EZH2;EZH2 target genes;prostate cancer (PCa);Triptolide; The histone methyltransferase EZH2 (enhancer of zeste homolog 2) plays critical roles in prostate cancer (PCa) development and is a potential target for PCa treatment. Triptolide possesses anti-tumor activity, but it is unknown whether its therapeutic effect relates with EZH2 in PCa. Here we described EZH2 as a target for Triptolide in PCa cells. Our data showed that Triptolide suppressed PCa cell growth and reduced the expression of EZH2. Overexpression of EZH2 attenuated the Triptolide induced cell growth inhibition. Moreover, Triptolide treatment of PC-3 cells resulted in elevated mRNA levels of target genes (ADRB2, CDH1, CDKN2A and DAB2IP) negatively regulated by EZH2 as well as reduced mRNA levelsan of EZH2 positively regulated gene (cyclin D1). Our findings suggest the PCa cell growth inhibition mediated by Triptolide might be associated with downregulation of EZH2 expression and the subsequent modulation of target genes.